Artemis Investment Management LLP Sells 3,850,879 Shares of Pfizer Inc. $PFE

Artemis Investment Management LLP reduced its holdings in Pfizer Inc. (NYSE:PFE) by 50.6% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 3,761,718 shares of the biopharmaceutical company’s stock after selling 3,850,879 shares during the quarter. Artemis Investment Management LLP’s holdings in Pfizer were worth $107,284,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Apella Capital LLC boosted its position in shares of Pfizer by 22.2% during the third quarter. Apella Capital LLC now owns 56,927 shares of the biopharmaceutical company’s stock worth $1,594,000 after purchasing an additional 10,327 shares in the last quarter. Valeo Financial Advisors LLC grew its holdings in shares of Pfizer by 1.9% during the third quarter. Valeo Financial Advisors LLC now owns 172,660 shares of the biopharmaceutical company’s stock worth $4,924,000 after buying an additional 3,282 shares in the last quarter. Quintet Private Bank Europe S.A. grew its stake in shares of Pfizer by 40.6% during the 3rd quarter. Quintet Private Bank Europe S.A. now owns 684,746 shares of the biopharmaceutical company’s stock worth $19,529,000 after acquiring an additional 197,811 shares in the last quarter. Vann Equity Management LLC acquired a new stake in Pfizer in the 3rd quarter valued at $325,000. Finally, City Center Advisors LLC acquired a new stake in shares of Pfizer in the third quarter valued at about $202,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Scotiabank lifted their price target on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday. Cantor Fitzgerald raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday. JPMorgan Chase & Co. dropped their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Sunday, September 13th. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.61.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA regimen, in combination with trastuzumab and pertuzumab, as a front-line maintenance treatment for adults with HER2-positive metastatic breast cancer. The expanded indication could increase TUKYSA’s addressable market and support oncology revenue growth. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Pfizer reported positive Phase 3 results for LITFULO in nonsegmental vitiligo, with meaningful facial and total-body repigmentation and favorable tolerability. Planned regulatory submissions could broaden the drug’s commercial opportunity and strengthen Pfizer’s immunology pipeline. Pfizer Posted Positive Phase 3 Vitiligo Results
• Neutral Sentiment: Cantor Fitzgerald raised its Pfizer price target from $27 to $28 but kept a neutral rating, implying limited upside at recent trading levels. Cantor Fitzgerald Raises Pfizer Price Target
• Neutral Sentiment: Pfizer declared its regular $0.43 quarterly dividend, equal to $1.72 annually and a yield of roughly 6%. The payout may attract income-focused investors, although the announcement itself does not change the company’s underlying earnings outlook. Pfizer Declares Fourth-Quarter 2026 Dividend
• Negative Sentiment: Analysts and financial commentary continue to flag risks behind Pfizer’s low valuation and high dividend yield, including a previously frozen payout, elevated debt, a multibillion-dollar write-down, and a reported payout ratio above earnings. These factors raise questions about long-term dividend reliability. Pfizer’s Yield and Dividend Risks
• Negative Sentiment: Pfizer plans to cut approximately 330 jobs at its Sicily, Italy, facility, highlighting ongoing cost pressure and restructuring needs. Investors may view the reductions as evidence of continued operational challenges despite Pfizer’s cost-cutting program. Pfizer to Cut Around 330 Jobs in Italy

Pfizer Trading Down 1.1%

PFE traded down $0.32 during trading on Thursday, reaching $27.68. 12,347,028 shares of the company’s stock were exchanged, compared to its average volume of 40,384,527. Pfizer Inc. has a one year low of $23.62 and a one year high of $29.21. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $157.80 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of 1.85 and a beta of 0.32. The firm has a fifty day moving average price of $27.56 and a two-hundred day moving average price of $26.48.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.